Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Pasithea Therapeutics Corp ( (KTTA) ) just unveiled an announcement.
On May 6, 2025, Pasithea Therapeutics Corp. entered into securities purchase agreements to sell shares of common stock and warrants, raising approximately $6.3 million in gross proceeds. The company plans to use the net proceeds of $4.3 million for general corporate purposes, including research, clinical trials, and potential acquisitions. The offering closed on May 7, 2025, with H.C. Wainwright & Co. acting as the exclusive placement agent.
More about Pasithea Therapeutics Corp
Pasithea Therapeutics Corp. is a clinical-stage biotechnology company focused on discovering, researching, and developing innovative treatments for central nervous system disorders, RASopathies, and MAPK pathway-driven tumors.
Average Trading Volume: 5,612,569
Technical Sentiment Signal: Sell
Current Market Cap: $4.5M
For a thorough assessment of KTTA stock, go to TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue